To sum, in this prospective, randomized controlled trial of twice-daily GABA, or co-treatment with GABA/GAD, in humans with T1D, we demonstrate a significant decrease in fasting and AUC glucagon in the GABA/GAD group, with a non-significant reduction in the GABA group at 12-months. Here, GAD1 is linked to type 1 diabetes mellitus.